Today: April 27, 2018, 10:32 am
  
Business

Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results

PR-Inside.com: 2017-05-19 14:04:02

SANTA CLARA, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces continued growth in 2017 with dramatic first quarter results.

In Q1 17 revenue reached NT$493 million, a 34% YOY (year-over-year) growth. Gross margin reached 49.3% with EPS (earnings per share) of NT$0.13. With the strong demand for Oncology and Immunology therapy, the company anticipates sustained revenue growth and increased profitability through 2017.

To achieve this growth CrownBio leveraged its existing platforms of patient-derived xenograft (PDX) and cell line derived xenograft pharmacology models, and expanded immuno-oncology translatable models while broadening the portfolio offering to inflammatory disease. This extensive portfolio supports the therapeutic continuum of Oncology, Cardiovascular, Metabolic, and Inflammatory disease research.

"The double and triple digit growth regionally, proves CrownBio's global reach and strong local presence is servicing our client base with sound scientific offerings," said Laurie Heilmann, SVP of Global Strategy, Business Development and Marketing, "Our Immuno-Oncology, Cardiovascular, and Metabolic translatable models, along with strong performance in Europe, US, and the Western APAC region were significant contributors to the growth."

Continued diversity across their service offerings, while remaining client centric, has enabled CrownBio to secure confidence by demonstrating growth in 75% of the top tier pharma companies. "CrownBio brings clarity to drug discovery with end to end solutions that help recognize the next clinical candidate sooner," said Dr. Jean-Pierre Wery, CEO. "We will further advance preclinical and clinical research through accelerating development of technologies, including biomarker discovery and precision diagnosis that are needed to bring the right molecule to market."

For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit www.crownbio.com.

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:

Jody Barbeau
Crown Bioscience Inc. marketing@crownbio.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire




# 533 Words
Related Articles
 
More From Business
Kiwis Are Still Not Taking Advantage of [..]
A recent opinion piece in Stuff speculated about the reasons why Kiwis have not been rushing to sign up to [..]
More Kiwis Homeowners Choose Open Floor Plan [..]
In New Zealand, the open floor plan is a common sight. Most common areas, especially the living room, dining room, [..]
Buy Single Use Laparoscopic Instruments from Endovision
Specialised Surgical company Endovision has a range of laparoscopic instruments available for sale through their website. The [..]
JCBI and Far Eastern Bank sign a [..]
Vladivostok, Russia & Tokyo, Japan, Apr 26, 2018 - (ACN Newswire) - JCB International Co., Ltd. (JCBI), the international operations [..]
Trillium Appoints Global Director of Engineering
TOKYO, Apr 20, 2018 - (ACN Newswire) - Trillium Secure, Inc., the global leader in delivering cyber security as a [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.